Research priorities in biomarkers and surrogate end-points.

Journal article

Ideal tests of the effects of therapeutic interventions measure the desired outcomes; however, the desired outcomes are not always easily measured or may be long-term objectives. Biomarkers and surrogate end-points are often cheaper and easier to measure and can be measured over a shorter time span. They can be used in screening, diagnosing, staging, and monitoring diseases, in monitoring responses to interventions, and in various aspects of drug discovery and development. They can be extrins...

Expand abstract

Authors: Aronson, J

• Publication status: Published
• Journal: British journal of clinical pharmacology
• Volume: 73
• Issue: 6
• Pages: 900-907
• Publication date: 2012-06-01
• DOI: 10.1111/j.1365-2125.2012.04234.x
• EISSN: 1365-2125
• ISSN: 0306-5251
• Language: English
• Keywords: Research Design; Biological Markers; Pharmacology, Clinical; Clinical Trials as Topic; Biomedical Research; Endpoint Determination; Humans